Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Itraconazole in BCR Prostate Cancer
NCT03513211Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- Aug 2018
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of SUBA itraconazole and hydroxychloroquine in prostate cancer (PCa) (2 arms), sponsored by St Vincent's Hospital. Primary endpoint: Recommended Phase II Dose of Hydroxychloroquine at 6 months. Started Aug 2018; status: completed.
02
Drugs
SUBA itraconazolehydroxychloroquine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03513211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513211.